StockMarketWire.com - PureTech Health said affiliate company Karuna Pharmaceuticals had started a key study for a treatment for psychosis in schizophrenia.
The so-called Phase 2 study would test least product candidate KarXT, or Karuna-Xanomeline-Trospium.
In a previous study, the treatment successfully demonstrated tolerability at a dose level exceeding those shown to be efficacious in previous studies of xanomeline alone.
Top-line data results of this latest study were expected at the end of 2019.
'"We are pleased with the progress Karuna has made to advance KarXT into a Phase 2 study, bringing us one step closer to potentially delivering the first new mechanism in more than 60 years for the treatment of psychosis in schizophrenia,' chief of research and strategy Eric Elenko said.
At 8:20am: [LON:PRTC] PureTech Health Plc share price was 0p at 161p
Story provided by StockMarketWire.com
Shares Magazine
Shares is the leading weekly publication for retail investors. It is packed with investment ideas, news and educational material to help build and run portfolios and get more from your money.
Investor Events
Shares puts on free Investor Events throughout the year across the country. They provide an opportunity for investors to learn more about companies on the stock market and hear from a range of investment experts including fund managers and Shares journalists.